Last ¥4,346 JPY
Change Today -13.50 / -0.31%
Volume 882.3K
As of 2:00 AM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (4523) Snapshot

Open
¥4,360
Previous Close
¥4,359
Day High
¥4,375
Day Low
¥4,338
52 Week High
07/31/14 - ¥4,443
52 Week Low
02/6/14 - ¥3,694
Market Cap
1.3T
Average Volume 10 Days
569.3K
EPS TTM
¥102.47
Shares Outstanding
296.6M
EX-Date
09/26/14
P/E TM
42.4x
Dividend
¥150.00
Dividend Yield
3.45%
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; Dacogen, a DNA methylation inhibitor; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus; BELVIQ, an antiobesity agent; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. Additionally, the company is involved in the research and development of various products under the areas of oncology and supportive care, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has collaboration agreement with Biogen Idec to develop and commercialize Alzheimer's disease treatments. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

Founded in 1941

eisai co ltd (4523) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eisai co ltd (4523) Key Developments

Eisai Submits Application for Indication Expansion of Fycompa

Eisai announced that it has submitted applications to regulatory authorities in the United States and Europe for the indication expansion of its in-house developed antiepileptic drug Fycompa as an adjunctive treatment of primary generalised tonic-clonic seizures. The application was based on a double-blind, randomised, placebo-controlled, multicentre, parallel-group clinical study to assess the efficacy and safety of adjunctive Fycompa therapy in 164 patients aged 12 years and older with uncontrolled primary generalised tonic-clonic seizures, receiving one to a maximum of three anti-epileptic drugs. The analysis of the study indicates that the product decreased primary generalised tonic-clonic seizures frequency and improved responder rates, the study's two primary result measures, when compared to placebo.

Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. Conclude License Agreement Concerning a New Proton Pump Inhibitor in Japan

Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai. Based on this agreement, Eisai will grant Zeria the exclusive rights to develop and co-promote, and the non-exclusive right to manufacture, E3710 in Japan. In addition, Eisai will receive down payment and additional royalties from Zeria, and after marketing authorization has been successfully obtained, Eisai will pay Zeria a certain consideration. While Zeria will develop E3710 and work to obtain marketing authorization, the two companies will collaborate on marketing E3710 after launch. E3710 is a novel PPI discovered by Eisai as a successor to Pariet, and compared to existing PPIs, potentially provides a stronger and a longer-lasting inhibitory effect on gastric acid secretion. E3710 shows promise as a best-in-class treatment which could shorten the treatment period and meet the needs of patients for whom existing PPIs are inadequate. This license agreement will enhance the product pipeline of Zeria, who focuses on gastrointestinal diseases as a key franchise area, and maximize the value of Eisai's compound. Both Eisai and Zeria have a strong track record in the field of gastrointernal diseases (Eisai with the PPI Pariet and the gastritis /gastric ulcer treatment Selbex, Zeria with the ulcerative colitis treatment Asacol and the world's first functional dyspepsia treatment Acofide) and will conduct co-promotional activities with the aim of bringing a product to the market for acid related diseases as soon as possible. Through this collaboration on E3710, Eisai and Zeria aim to satisfy the medical needs of acid related diseases and further contribute to the treatment of patients.

Eisai Co., Ltd Submits Marketing Approval Applications for Anticancer Agent Lenvatinib Simultaneously in Europe and U.S

Eisai Co., Ltd. announced that it has submitted applications to regulatory authorities in the U.S. and Europe (FDA and EMA respectively) for marketing approval of its novel in-house developed anticancer agent lenvatinib mesylate (lenvatinib) as a treatment for progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). An application seeking marketing approval of lenvatinib for the indication of thyroid cancer was submitted in Japan on June 26, 2014. Lenvatinib was granted Orphan Drug Designation for thyroid cancer in Japan, Europe and the U.S. Lenvatinib was also granted an accelerated assessment in Europe by the EMA, as it is a new medicine expected to be of major public health interest, particularly from the viewpoint of therapeutic innovation. Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of several different RTKs including VEGFR, FGFR, PDGFRa, KIT and RET, involved in angiogenesis and tumor proliferation. This potentially makes lenvatinib a first-in-class treatment in thyroid cancer, especially given that it simultaneously inhibits the kinase activities of FGFR as well as VEGFR. The applications submitted were based on a Phase III clinical study, known as the SELECT (Study of (E 7080) LE nvatinib in Differentiated Cancer of the T hyroid) trial, which was a multicenter, randomized, double-blind, placebo-controlled study of lenvatinib in 392 patients with RR-DTC and radiographic evidence of disease progression within the prior 13 months (patients may have received =1 prior VEGFR-targeted therapies). The study was conducted by Eisai in cooperation with SFJ Pharma Ltd.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥4,345.50 JPY -13.50

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4523.
View Industry Companies
 

Industry Analysis

4523

Industry Average

Valuation 4523 Industry Range
No financial data is available for 4523.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.